コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 mized to receive either placebo (n= 2031) or acadesine (0.1 mg x kg(-1) x min(-1); n=2012) by intrave
2 participants were randomized 1:1 to receive acadesine (0.1 mg/kg per minute for 7 hours) or placebo
3 id (twice the shed blood volume) plus either acadesine (5 mg/kg bolus + 1 mg/kg x 60 min, n = 10) or
5 perioperative and postoperative infusion of acadesine, a first-in-class adenosine-regulating agent,
7 ents undergoing CABG surgery, treatment with acadesine before and during surgery can reduce early car
9 refore, we questioned whether use of the ARA acadesine-by increasing interstitial adenosine concentra
10 hrough postoperative day 4 demonstrated that acadesine decreased by 89% the number of deaths from 13.
11 high-risk patients undergoing CABG surgery, acadesine did not reduce the composite of all-cause mort
12 cacy of the adenosine regulating agent (ARA) acadesine for reducing long-term mortality among patient
13 e placebo group and 76 of 1493 (5.1%) in the acadesine group (odds ratio, 1.01 [95% CI, 0.73-1.41]).
15 S: The Reduction in Cardiovascular Events by Acadesine in Patients Undergoing CABG (RED-CABG) trial,
17 randomized to receive placebo (n = 1,346) or acadesine (n = 1,352) by intravenous infusion (0.1 mg/kg
19 27.8% (15 of 54; placebo) to 6.5% (3 of 46; acadesine) (p = 0.006), with the principal benefit occur
23 cidence of adverse events was similar in the acadesine vs placebo groups, with the exception of a tra
25 me conditions, the acute salutary effects of acadesine were probably overwhelmed by polymicrobial sep
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。